2023
DOI: 10.1038/s41598-023-49277-w
|View full text |Cite
|
Sign up to set email alerts
|

Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study

Julia Hernandez-Baixauli,
Gertruda Chomiciute,
Juan María Alcaide-Hidalgo
et al.

Abstract: Hypertriglyceridemia (HTG) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). One of the multiple origins of HTG alteration is impaired lipoprotein lipase (LPL) activity, which is an emerging target for HTG treatment. We hypothesised that early, even mild, alterations in LPL activity might result in an identifiable metabolomic signature. The aim of the present study was to assess whether a metabolic signature of altered LPL activity in a preclinical model can be identified in hum… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 67 publications
(79 reference statements)
0
0
0
Order By: Relevance
“…P407 is a lipoprotein lipase inhibitor that affects lipid metabolism. Injection of P407 can rapidly and consistently increase serum triglycerides (TG), total cholesterol (TC), LDL and apolipoprotein B levels (Hernandez-Baixauli et al, 2023).…”
Section: Animalsmentioning
confidence: 99%
“…P407 is a lipoprotein lipase inhibitor that affects lipid metabolism. Injection of P407 can rapidly and consistently increase serum triglycerides (TG), total cholesterol (TC), LDL and apolipoprotein B levels (Hernandez-Baixauli et al, 2023).…”
Section: Animalsmentioning
confidence: 99%